PD-1 + TIGIT + CD8 + T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma

In conclusion, PD-1+ TIGIT+ CD8+ T-cell populations are associated with accelerated disease progression and poor outcomes in HBV-HCC, which might not only have important clinical implications for prognosis but also provide a rationale for new targets in immunotherapy.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

In conclusion, circulating microRNAs, particularly the miR-125b, may serve as promising biomarkers for the early diagnosis of HBV-related HCC. However, larger and more rigorous studies are needed to confirm our conclusions.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
CONCLUSIONS: Our results demonstrated that a web-based calculator including age, sex, AFP, and PIVKA-II accurately predicted the presence of HCC in patients with CHB. ClinicalTrials.gov Identifier: NCT03047603
Source: Clinical Chemistry - Category: Chemistry Authors: Tags: Cancer Diagnostics (since 2002) Source Type: research
This study aimed to investigate the levels of growth differentiation factor 15 (GDF15), a stress-induced factor, and sex hormones in male patients with HBV-related hepatocellular carcinoma (HCC) and the association between the two. In this study, we recruited 298 male participants including 83 healthy individuals as controls, 67 patients with chronic hepatitis B (CHB), 56 patients with HBV-related liver cirrhosis (HBV-related LC), and 92 patients with HBV-related HCC. Serum levels of GDF15, total testosterone (TT), estradiol (E2), free testosterone (FT) and other biochemical variables were measured. Serum GDF15 levels were...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
ConclusionsThe additive risk of T2DM for HCC development was highest in patients with NASH. HCC risk may vary depending on the underlying etiology.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
This study aimed to investigate the levels of growth differentiation factor 15 (GDF15), a stress-induced factor, and sex hormones in male patients with HBV-related hepatocellular carcinoma (HCC) and the association between the two. In this study, we recruited 298 male participants including 83 healthy individuals as controls, 67 patients with chronic hepatitis B (CHB), 56 patients with HBV-related liver cirrhosis (HBV-related LC), and 92 patients with HBV-related HCC. Serum levels of GDF15, total testosterone (TT), estradiol (E2), free testosterone (FT) and other biochemical variables were measured. Serum GDF15 levels were...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
idinis Liver cancer is one of the leading causes of death worldwide due to late diagnosis and scarcity of treatment options. The major risk factor for liver cancer is cirrhosis with the underlying causes of cirrhosis being viral infection (hepatitis B or C), metabolic deregulation (Non-alcoholic fatty liver disease (NAFLD) in the presence of obesity and diabetes), alcohol or cholestatic disorders. Lysophosphatidic acid (LPA) is a bioactive phospholipid with numerous effects, most of them compatible with the hallmarks of cancer (proliferation, migration, invasion, survival, evasion of apoptosis, deregulated metabolism, ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract BACKGROUND: Our study aims to detect the sensitivity of the new biomarker miR-212 existing in serum exosomes along with other hepatocellular carcinoma biomarkers such as AFP (alpha-fetoprotein), CA125 (carbohydrate antigen-ca125), and Hbx protein in the diagnosis of HBV-related liver diseases. We also aim to study the roles of these biomarkers in the progression of chronic hepatitis B and provide scientific data to show the clinical value of these biomarkers. Methods: We selected 200 patients with HBV-infection (58 cases of chronic hepatitis B, 47 cases of hepatocellular carcinoma, 30 cases of compensator...
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research
Authors: Crespo García J, Andrade RJ Abstract Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths worldwide. Up to 80% of patients with HCC have concomitant cirrhosis as a result of hepatitis B or C virus, alcohol abuse, or non-alcoholic steatohepatitis. PMID: 31566408 [PubMed - as supplied by publisher]
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
N-glycopeptide signatures of IgA2 in serum from patients with hepatitis B virus-related liver diseases. Mol Cell Proteomics. 2019 Sep 09;: Authors: Zhang S, Cao X, Liu C, Li W, Zeng W, Li B, Chi H, Liu M, Qin X, Tang L, Yan G, Ge Z, Liu Y, Gao Q, Lu H Abstract N-glycosylation alteration has been reported in liver diseases. Characterizing N-glycopeptides that correspond to N-glycan structure with specific site information enable better understanding of the molecular pathogenesis of liver damage and cancer. Here, unbiased quantification of N-glycopeptides of a cluster of serum glycoproteins wi...
Source: Molecular and Cellular Proteomics : MCP - Category: Molecular Biology Authors: Tags: Mol Cell Proteomics Source Type: research
ConclusionRepeat hepatectomy has favorable long-term outcomes. Cirrhosis and HBV not treated with antiviral therapy were associated with immediate postoperative morbidity. Serum AFP> 20 ng/mL at first resection, PH, and GVI at recurrence are independent prognostic factors. For patients without PH, TNM staging can predict prognosis.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Carcinoma | Cirrhosis | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Urology & Nephrology